The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid protein formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions. The inventive methods can also yield a higher stability of a liquid protein formulation.

Methods for identifying cancer patients amenable to anti-cancer immunotherapy are provided along with methods of monitoring cancer therapy. Also provided are methods of treating cancer patients amenable to anti-cancer immunotherapy. The methods involve determining the level of CD127 <low> PD-1 <low> T cells. The patients are treated with an immune checkpoint inhibitor, such as an anti-CTLA-4 antibody, e.g. ipilimumab.

The invention provides compositions and methods for treating optic neuropathic disorders.

Modified bovine G-CSF polypeptides and uses thereof are provided.

Described herein is the use of CSF, more particularly external CSF or CSF-like compositions for the treatment and prevention of different diseases. More particularly, the application provides for the administration of CSF to the intrathecal space or the cerebral ventricles of a patient to increase intracranial pressure and/or CSF flow.

The invention provides non-hormonal Vitamin D conjugated to G-CSF or compounds with G-CSF activity or GM-CSF or compounds having GM-CSF activity singly or in combination that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.

Provided is a cytokine combination for treating a tumor and/or preventing recurrence or metastasis of the tumor. The cytokine combination comprising at least three cytokines selected from the following groups: IL(interleukin)12 or a functional variant thereof, GMCSF (granulocyte-macrophage colony-stimulating factor) or a functional variant thereof, FLT3L (FMS-like tyrosine kinase 3 ligand) or a functional variant thereof, IL2 or a functional variant thereof, IL15 or a functional variant thereof, IL21 or a functional variant thereof, and IL7 or a functional variant thereof. Also provided is a nucleic acid molecule encoding the cytokine combination and a vector thereof, a cell, a pharmaceutical composition, and a application thereof for the manufacture of a drug for treating the tumor and/or preventing recurrence or metastasis of the tumor.

The disclosure provides immunogenic peptides, compositions, means, and methods for treating Alzheimer's disease or mild cognitive impairment. The disclosure further provides means and methods for diagnosing patients, selecting patients for treatment, and/or evaluating the efficacy of treatment for Alzheimer's disease or mild cognitive impairment.

The disclosure provides immunogenic peptides, compositions, means, and methods for treating Alzheimer's disease or mild cognitive impairment. The disclosure further provides means and methods for diagnosing patients, selecting patients for treatment, and/or evaluating the efficacy of treatment for Alzheimer's disease or mild cognitive impairment.

The present disclosure provides a therapy for diabetes that targets abnormal stem cells in combination with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabetes-related diseases and disorders and/or symptoms that targets abnormal stem cells in combination with stem cell migration. In one embodiment, the present disclosure provides diagnosis of diabetes and/or diabetes-related diseases and disorders and/or symptoms, or the risk thereof, using abnormal stem cell migration and/or residence as an indicator.